title: Community experience with bortezomib in patients with multiple myeloma.
abstract: Community practice experience allows a nonselective care of patient using information derived from a more controlled clinical trial environment. We present our community experience with multiple myeloma patients with advanced age, long disease duration since diagnosis, advanced stage, multiple prior therapies including stem cell transplantation, co-morbidities, and other poor prognostic features, such as low albumin, high B-2 microglobulin, renal failure, and the presence of poor risk chromosomal abnormalities. Our response rates are comparable to those from clinical trials. Bortezomib is well tolerated in this population of multiple myeloma patients with the exception of infection adverse events that are generally mild grade 1-2.
authors.affiliation: Department of Hematology/Oncology, Marshfield Clinic-Weston Center, Weston, WI 54476, USA. onitilo.adedayo@marshfieldclinic.org
authors.forename: Adedayo A
authors.initials: AA
authors.lastname: Onitilo
authors.forename: Jessica
authors.initials: J
authors.lastname: Engel
authors.forename: Bankole
authors.initials: B
authors.lastname: Olatosi
authors.forename: Seth
authors.initials: S
authors.lastname: Fagbemi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D003154:Community Medicine; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology*; D011719:Pyrazines / Q000627:therapeutic use*; D015996:Survival Rate
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib